Mumbai-based Concept Pharmaceuticals Ltd has launched two products Anaflox and Oflab recently.

Anaflox is a combination of Ofloxacin 200 mg and Tinidazole 600 mg and used in diarrhoea and dysentery, mixed infections due to anaerobic, aerobic bacteria and protozoa.

Oflab is the first ever combination of ofloxacin and lactobacillus and is useful in typoid, pyrexia of unknown origin, genito-urinary infections, multi-drug resistant tuberculosis, respiratory tract infections, post-surgical infections etc. It is available in 100DT, 200, 300 and 400 mg tablet dosages.

K Gopalakrishnan, general manager of the Rs 35 crore annual sales turnover ethical pharma division of the company said that Concept has set a target of Rs 2.5 crores for Anaflox and Rs 4 crores for Oflab for the first year.

The total market size of ofloxacin-tinidazole combination, he said, was Rs 14 crores growing at 260 per cent for the directly marketed products whereas it was Rs 250 crore at a growth rate of 5 per cent for the indirectly marketed products. The combination's direct marketing is a very strong growth area, he noted.

As for the ofloxacin combination with lactobacillus, he said, the market size was Rs 107 crore and growing at the rate of 50 per cent.